Kornimate/medical-research-clean huggingface dataset:
prognosis of geriatric patients 1 year after hospitalization for covid-19

Conditions: COVID-19

Summary: old patients hospitalized in acute geriatric units are characterize by advanced age, frailty, high number of comorbidities, cognitive impairment and loss of functional autonomy. although, intra-hospital mortality in geriatric population (out of covid) is low (6%) the long-term prognosis is often worse (30 to 60% of loss of autonomy and 30% of one-year mortality among hospital survivors). for geriatric patients with covid19, intra-hospital mortality is higher than in younger covid patients (1), but also higher than in geriatric patients outside the covid context (30 vs 6% (2, 3)). our hypothesis is that geriatric patients surviving hospitalization for covid-19 have a worse vital and functional prognosis at 12 months than geriatric patients surviving hospitalization for another medical reason.

old patients hospitalized in acute geriatric units are characterize by advanced age (average 85 years), frailty, high number of comorbidities, cognitive impairment and loss of functional autonomy.these particular state leads to multiple decompensations and the reason for initial hospitalization is often only the "tip of the iceberg". although, intra-hospital mortality in geriatric population (out of covid) is low (6%) the long-term prognosis is often worse (30 to 60% of loss of autonomy and 30% of one-year mortality among hospital survivors). for geriatric patients with covid19, intra-hospital mortality is higher than in younger covid patients (1), but also higher than in geriatric patients outside the covid context (30 vs 6% (2, 3)). this excess mortality is all the more surprising as these patients seem to have fewer comorbidities than those usually hospitalized in acute geriatric units. our hypothesis is that geriatric patients surviving hospitalization for covid-19 have a worse vital and functional prognosis at 12 months than geriatric patients surviving hospitalization for another medical reason.

Eligibility criteria:
inclusion criteria: * age \>=75 years * hospitalized for medical reason in acute geriatric unit * alive at hospital discharge exclusion criteria: * patients hospitalized for surgical reason * patients under legal protection * patient refusal

Keywords: covid-19 1-year prognosis older patients
levels of inflammation in people with cardiovascular disease (poseidon)

Conditions: Cardiovascular Risk; Heart Failure; Chronic Kidney Disease

Summary: this study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease). participants will continue their normal care and will not get any treatment other than those the study doctor has prescribed.


Eligibility criteria:
inclusion criteria: 1. informed consent obtained before any study-related activities. study-related activities are any procedures that are carried out as part of the study. 2. age 18 years or above at the time of signing the informed consent. 3. presence of ascvd (atherosclerotic cardiovascular disease) and/or hf (heart failure) 4. presence of serum creatinine in the medical chart within 24 months prior to signing of informed consent (for ascvd patients only). exclusion criteria: 1. previous participation in this study. participation is defined as having given informed consent in this study. 2. current participation (i.e., signed informed consent) in any other interventional clinical study. 3. any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization). 4. clinical evidence, or suspicion of, active infection within the last 60 days. 5. mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation
clinical efficacy of two topical dry eye drops for central corneal stain clearing over 90 days

Conditions: Dry Eye

Summary: this study will be a randomized, double-blind prospective in 3 clinical sites to compare the efficacy of two currently approved topical ophthalmic drops in the clearing central corneal staining in 90 days prior to elective cataract or lasik surgery.

the study will be a randomized, double-blind prospective study in 3 sites in the us to compare efficacy of improvement in central corneal staining with fluorescein dye evaluations at slit lamp exam, secondarily improvement in osdi questionnaire with additional questions regarding dysgeusia, blurriness, and sensation of burning, improvements in corneal topography and improvements in schirmer's testing. 100 study subjects 18-85 male or female will be enrolled in the nashville, beverly hills and st. louis areas who are generally healthy with central corneal staining and scheduled for uncomplicated phacoemulsification or uncomplicated lasik.

Eligibility criteria:
inclusion criteria: 1. subject is able to read, understand and sign informed consent. 2. provision of signed and dated informed consent and hipaa authorization . 3. willingness to comply with study procedures and availabilty for duration of study. 4. aged 18-85, male or female 5. minimum of 5 central corneal superficial punctate keratitis spots. 6. normal eyelid anatomy 7. highly effective contraception for at least 1 month prior to screening and agreement to use effective contraception during study participation and for an additional 4 weeks after study drug discontinuation. 8. postmenopausal or surgical sterilization. - exclusion criteria: 1. known hypersensitivity or contraindication to investigational product. 2. contact lens use within one month prior to screening 3. unwilling to discontinue contact lens. 4. pregnancy or lactation. 5. topical or nasal vasoconstrictors within 14 days prior to screening or unable to refrain from same. 6. ocular surgery or eyelid surgery within 6 months prior to screening 7. subjects can be on the following medications if they have been on a stable dose for 12 weeks: loteprednol, tetracycline, omega 3, anticholinergics, anticonvulsants, antidepressants, retinoids, systemic immunosuppressives including oral steroids, non-steroidals, antihistamines, mast cell stabilizers, punctal plugs, corticotropin repository or glaucoma medications. 8. abstain from eyelast growth products containing prostaglandin 9. must not have had penetrating intraocular surgery, refractive surgery, cornea transplant, eyelid surgery within 6 months prior to visit 1 10. febrile illness within 1 week 11. treatment with another investigational drug or intervention within one month 12. history of herpetic keratitis. 13. serious or severe disease or uncontrolled medical condition that in the judgment of the investigator could confound study study assessments or limit compliance. 14. use of new prescription eyedrop within 90 days of screening. 15. change in systemic medication within 90 days of screening 16. anticipated relocation or extensive travel during study period. -
ultrasound measurement of optic nerve sheath diameter as non-invasive detector of raised intracranial pressure in adult traumatic and non-traumatic neurocritical patients in icu

Conditions: Ultrasound; Optic Nerve Sheath Diameter; Non-Invasive; Intracranial Pressure; Neurocritical; Intensive Care Unit

Summary: this study aimed to assess the role of ultrasound as a non-invasive method (bedside) to measure the rise of intracranial pressure by measuring the optic nerve sheath diameter in traumatic and nontraumatic neurocritical patients.

measurement of intracranial pressure (icp) is crucial in the management of many neurological conditions. however, due to the invasiveness, high cost, and required expertise of available icp monitoring techniques, many patients who could benefit from it do not receive it. as a result, a substantial effort has been made to explore and develop novel non-invasive icp monitoring techniques to improve the overall clinical care of patients suffering from icp disorders.

Eligibility criteria:
inclusion criteria: * age \>18 years old. * both sexes. * patients with suspected high intracranial pressure. exclusion criteria: * cases suffering from eye disease or optic nerve problems (glaucoma, optic nerve tumor, neuritis, orbital fracture). * patients suffering from mental illness render them incapable of communication \& cooperation (for example: dementia and irritability). * any previous intensive care surgeries \& hyperthyroidism (due to exophthalmos)
assessment of suicidality in epilepsy - rating tools

Conditions: Epilepsy

Summary: this will be a cross-sectional study enrolling 200 outpatients/inpatients with treatment resistant partial epilepsy for at least two years, receiving 1-3 aeds. the study will consist of one or two visits, each lasting 1-2 hours. all subjects will complete visit 1. twenty five percent of the subjects will return for visit 2. the study will assess the prevalence of depression and suicidal thoughts and the feasibility of using the proposed psychiatric rating scales in future epilepsy clinical trials. this study will also provide an estimate of the proportion of patients with epilepsy (pwe) who may be ineligible for future trials.

in light of the recent issues regarding antiepileptic drugs and suicidality, the epilepsy study consortium is proposing a pilot study. several scales to assess suicidality and screen for depression and anxiety disorders will be administered to a group of epilepsy patients with characteristics similar to patients who are usually enrolled in epilepsy clinical trials. the study will assess the prevalence of depression, suicidal thoughts, and behavior and the feasibility of using the proposed psychiatric rating scales in future epilepsy clinical trials. this study will also provide an estimate of the proportion of patients with epilepsy who may be ineligible for future trials because they have had active suicidal thoughts in the last 6 months, suicidal behavior in the last 2 years or a current major depressive episode.

Eligibility criteria:
inclusion criteria: * partial epilepsy for at least two years, confirmed with eeg studies * aged 18 to 70 years-old * proficient in english * having a minimum of a 4th grade reading level * having been on stable doses and type of aeds for the previous two months * have at least 1 observable partial seizure (simple partial with motor component, complex partial or secondarily generalized tonic clonic seizure) per month for the past 6 months * is currently receiving 1-3 aeds * has failed at least 2 aeds (including current therapy) exclusion criteria: * non-epileptic seizures with or without comorbid epileptic seizures * subjects who currently carry a diagnosis of a major psychotic disorder * subjects who are currently taking an investigational medication * subjects with a known history of alcoholism, drug abuse, or drug addiction within the past 2 years
a phase ib/ii study of shr-a1811 injection in breast cancer

Conditions: Breast Cancer

Summary: to evaluate the safety, tolerability and efficacy of shr-a1811 in combination with pyrotinib or pertuzumab or adebrelimab or albumin-bound paclitaxel in patients with breast cancer.


Eligibility criteria:
inclusion criteria: 1. women aged 18 to 75 (inclusive) 2. breast cancer confirmed by histology or cytology. 3. ecog score is 0 or 1 4. an expected survival of ≥ 12 weeks 5. at least one measurable lesion according to recist v1.1 criteria 6. have adequate renal and hepatic function 7. patients voluntarily joined the study and signed informed consent exclusion criteria: 1. have other malignancies within the past 5 years 2. active central nervous system metastasis without surgery or radiotherapy 3. presence with uncontrollable third space effusion 4. have undergone other anti-tumor treatment within 4 weeks before the first dose 5. immunosuppressant or systemic hormone therapy was used within 2 weeks prior to the first dose 6. any active autoimmune disease or a history of autoimmune disease 7. a history of immune deficiency 8. clinically significant cardiovascular disorders 9. clinically significant history of lung disease 10. the toxicity from previous anti-tumor treatment has not recovered to ≤ grade i 11. known hereditary or acquired bleeding tendency 12. active hepatitis and liver cirrhosis 13. presence of other serious physical or mental diseases or laboratory abnormalities
expanded access to risankizumab

Conditions: Crohn's Disease; Ulcerative Colitis (UC)

Summary: this is an expanded access program (eap) for eligible participants with crohn's disease (cd). this program is designed to provide access to risankizumab, prior to approval by the local regulatory agency, to patients with the highest unmet need and an urgent need for treatment, where risankizumab may prolong survival, prevent occurrence of clinical events associated with significant morbidity and/or mortality, or stabilize a progressive debilitating disease. availability will depend on a review of the eligibility of the patient and local approval status of risankizumab for cd. a medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.


Eligibility criteria:

Keywords: expanded access pre-approval access compassionate use special access program named patient basis special access scheme
an open label study to evaluate the efficacy of airgent in treating damaged and wrinkled skin

Conditions: Wrinkles or Damaged Skin Condition

Summary: the primary objective of this study is to evaluate the effectiveness of treatment of wrinkles or damaged skin with the airgent device. the secondary objective of this study are to: * evaluate subjects' satisfactory of the treatment. * demonstrate the safety of the airgent treatment by evaluation of adverse events.

each subject will attend the clinic for the screening visit, 3 or 4 treatment visits 3-4 weeks apart, and number of follow-up visits (three at least). evaluation of results of the performed treatments will be performed in course of the next treatment visit (prior to performance the next treatment) and at follow-up visits at 1, 3 and 6 months after the last treatment in session. additional evaluation visits at 9 and 12 months after completion the treatment session can be performed upon decision of the investigator in case when considerable improvement is recorded during the 6-months evaluation visit. biopsies from up to five subjects treated for stretch marks will be collected at the time of 3-months evaluation visit, from treated and untreated zone (one of each). subjects will be requested to refrain from using any other method of skin rejuvenation for the entire duration of the study.

Eligibility criteria:
inclusion criteria: * females and males in good general health 18-65 years old * subject that are capable of reading, following directions, and understanding the procedure to be applied and that are obligated to forgo any other method of skin rejuvenation treatment for the entire study period. exclusion criteria: * medical or psychiatric conditions that can affect the subject's ability to give informed consent, or complete the study. * pregnant or lactating females. * other known diseases including diabetes, autoimmune disorders, epilepsy, severe migraines chronic liver or kidney * disease or contagious diseases, such as hiv or hepatitis * participation in a clinical trial within the last 30 days. * subjects on any medication (chronic use) that would affect the characteristic of the skin (medical or hormonal), such as nsaid, blood thinning medications, immunosuppressive drugs, steroids, vitamin e supplements and isotretinoins within one month prior to enrollment. * subjects who have any form of suspicious lesion on the treatment area. * subjects with history of keloid formations or hypertrophic scarring. * subjects with permanent makeup/ tattoo (in the treated area). * subjects with any cutaneous inflammation on the treatment area such as herpes or acne. * subjects with known sensitivity to hyaluronic acid or to egg products. * subjects with clotting disorders. * subjects addicted to drug or alcohol. * subjects who underwent any aesthetic procedure in the treated area or adjacent to it.

Keywords: remodeling airgent hyaluronic acid collagen formation
mini- percutaneous nephrolithotomy versus standard percutaneous nephrolithotomy in the treatment of renal stones.

Conditions: Urolithiasis; Stone;Renal; Nephrolithiasis; PNL; PCNL; NEPHROLITHOTOMY; MINIPERC

Summary: the eua urolithiasis guidelines panel meta-analysis suggest that mpnl is at least as efficacious and safe as spnl for the removal of renal calculi. however, the quality of the evidence was poor, drawn mainly from small studies, the majority of which were single-arm case series, and only one of which was rct. the risks of bias and confounding were high, highlighting the need for more reliable data from rcts. so, the panel recommended for more clinical research . the aim of this study is to compare between pnl and mpnl through a randomized controlled trial.


Eligibility criteria:
inclusion criteria: 1. patient 18 years or older. 2. asa i or ii 3. renal stones ≥ 2 cm 4. lower calyceal stone ≥ 1 cm 5. failure of other modalities of treatment as eswl and rirs. exclusion criteria: 1. s.creatinine \> 2mg/dl. 2. patients with active uti. 3. patients on anticoagulant. 4. age \<18 years. 5. ureteral obstruction preventing the insertion of a ureteral stent.

Keywords: urolithiasis stone, renal nephrolithiasis pnl pcnl nephrolithotomy miniperc mini-perc blood loss nephrostomy size
pediatric pain rehabilitation program

Conditions: Pediatric Chronic Pain

Summary: the purpose of this study is to describe the demographic, medical, and psychological/behavioral characteristics of children and adolescent patients admitted to the cleveland clinic children's hospital's pain rehabilitation program. the data will also be used to evaluate the clinical outcomes of patients admitted to the program as well as to examine the impact of various background factors on clinical outcomes.


Eligibility criteria:
inclusion criteria: * admitted into the cleveland clinic children's hospital's pain rehabilitation program exclusion criteria: -

Keywords: pediatric chronic pain
proact - pre-operative arimidex compared to tamoxifen

Conditions: Breast Cancer

Summary: the purpose of this study is to compare tamoxifen, versus a newer treatment, arimidex, which we already know to be well tolerated. the main objectives of this research study are to see whether using these drugs will shrink down tumours before surgery and to see if any shrinkage in the tumour affects the extent of surgery that is required.


Eligibility criteria:
inclusion criteria: * operable or potentially operable breast cancer * invasive breast cancer proven to be hormone-sensitive (er+/pr+) * patients who might benefit from endocrine treatment prior to surgery * postmenopausal * signed written informed consent exclusion criteria: * inoperable breast cancer * patient unwilling to undergo surgery * any reason why the patient may not be able to conform to study requirements * any previous treatment for breast cancer * previous tamoxifen use as a part of breast cancer prevention trials * not willing to stop taking drugs that affect sex-hormones such as hrt * previous history of breast cancer * previous history of invasive malignancy within the last 10 years * any other severe disease that may prevent surgery, place the patient at risk, or influence the study results * treatment with an experimental drug within the last 3 months * risk of transmitting hiv, hepatitis b or c
incidence and course of stress hyperglycemia in critically ill children admitted to picu of assiut university children hospital

Conditions: Stress Hyperglycemia

Summary: detection of the prevelance of stress hyperglycemia in patients admitted to pediatric intensive care unit of assiut university children hospital , asses its pattern ,course ,risk factors, its relation to the outcome and its management.

critically ill patients often develop endocrine and metabolic changes, particularly disruptions of glucose homeostasis that result in hyperglycemia and hypoglycemia.stress hyperglycemia commonly occurs in children with critical illnesses. stress hyperglycemia results from increased gluconeogenesis relative to the clearance of glucose as well as from the development of insulin resistance affecting glucose uptake. these mechanisms are mediated through increased production of counteracting hormones (i.e., epinephrine, norepinephrine, cortisol, glucagon, and growth hormone). furthermore, stress hyperglycemia is associated with pro-inflammatory cytokines, oxidative stress, and therapeutic interventions. those factors in turn inhibit the secretion of insulin by pancreatic β cells through α-adrenergic receptor stimulation, interfere with insulin receptor signaling and/or insulin-regulated glucose channels, and directly interfere with proper glucose transport and utilization in peripheral cells. several studies have demonstrated the association of stress hyperglycemia in critically ill children with mortality. specifically, peak and duration of stress hyperglycemia appear to be associated with mortality. peak blood glucose concentrations tend to be much higher in non survivors compared with survivors. similarly, non survivors tend to have exposure to longer duration of stress hyperglycemia compared with survivors. this association of stress hyperglycemia with mortality appears across different pediatric disease states, including septic shock, burns, traumatic brain injury, post cardiac surgery, and trauma. additionally, stress hyperglycemia is associated with longer periods of icu and hospital stay and more frequent nosocomial infections, including surgical site infections in critically ill children. while all these studies demonstrate strong associations between stress hyperglycemia and poor clinical outcomes, they do not necessarily demonstrate a cause and effect relationship.

Eligibility criteria:
inclusion criteria: * critically ill children admitted to emergency and intensive care unit with blood glucose level more than or equal 200 mg\\dl. exclusion criteria: * documented cases of diabetes mellitus